Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Dec 7;5:100. doi: 10.1038/s41698-021-00239-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a Number of stable disease points that surpassed the numerical cutoffs per individual NGS assay (%Δt-MAD or ΔVAF_mean) and in combination. Gray stacks indicate the percentage of points with inconclusive NGS assay values leading to clinical progression. Blue stacks represent points that showed sustained %Δt-MAD and/or ΔVAF_mean increase leading to clinical progression, indicating early molecular progression. b Patients identified with early molecular progression were enriched in the ALK ctDNA (+) group. c Breakdown of 22 patients with early molecular progression based on NGS assays. d Comparison of called lead times based on NGS assays. e Comparison of called lead times based on therapy lines. f Comparison of cases with called lead time showing significant difference in days to radiographic progression versus molecular progression. g Length of lead time per therapy line was significantly correlated with duration of progression-free response to the respective treatment. h Lead times in cases with wild-type TP53 (TP53^wt) were significantly longer compared to cases with mutated TP53 (TP53^wt) detected by tNGS. The box plot show the the median, upper quartile, and lower quartile values. The whiskers indicate minimum and maximum values.